{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"RR (sCR+CR+VGPR+PR) according to uniform international response criteria and CBR (RR+MR according to modified EBMT criteria) will be assessed with SPEP, 24h UPEP, serum urine immunofixation, and serum free light chain assay at the start of each cycle and after completion of the 4th cycle.","groups":[{"description":"Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.\n\nglutamine: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.\n\nquality-of-life assessment: Ancillary studies","id":"OG000","title":"Arm I (Preventative Nutritional Supplementation)"},{"description":"Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.\n\nquality-of-life assessment: Ancillary studies\n\nplacebo: Given PO","id":"OG001","title":"Arm II (Placebo)"}],"populationDescription":"Subject data not collected due to low accrual. Research cancelled","reportingStatus":"POSTED","timeFrame":"up to 4 months from start of study","title":"RR (Complete Remission [sCR+CR+Very Good Partial Remission [VGPR]+Partial Remission [PR])","type":"SECONDARY"}